Here is a good example of FDA guidance on the issue.[1]
FDA acknowledges that FVIII levels can serve as a proxy for clinical outcome (reduced bleeding episodes) in hemophilia A.
Our understanding of what is "normal" in FVIII blood levels is such that a single arm, surrogate biomarker study is sufficient for approval.
[1]https://www.fda.gov/downloads/BiologicsBloodVaccines/Guidanc...
Could you help by pointing out where they talk about not obtaining baseline/control data? After a quick glance, they only seem to mention using a within-subject design.
Sorry, misread your reply. Yes, they do an internal baseline/control, but don't have a control arm (either placebo or active comparator) in the trial.
That was the focus of the JAMA article.
Why is this the case? Wouldn’t there be concerns that a study population might be different from the general population and thus require an internal control?